Mallia Therapeutics reports on novel therapeutic approach for treating alopecia at the annual meeting of the European Hair Research Society (EHRS)
|
EQS-News: Mallia Therapeutics
/ Key word(s): Conference/Research Update
Mallia Therapeutics reports on novel therapeutic approach for treating alopecia at the annual meeting of the European Hair Research Society (EHRS) Erlangen, Germany, May 21, 2025 - Mallia Therapeutics GmbH, a biopharmaceutical company specializing in the development of innovative therapies for hair loss, announced today that Prof. Dr. Alexander Steinkasserer, co-founder and CEO of Mallia Therapeutics, will participate in this year's annual meeting of the European Hair Research Society (EHRS) from May 29 to 31, 2025, in Warsaw. In a presentation titled “Soluble CD83 as a novel therapeutic approach for the treatment of alopecia,” he will present the latest scientific findings on Mallia's proprietary sCD83-based approach to hair loss. The presentation will take place on May 30 as part of the “Progress in Research 2” session, from 11:00 a.m. to 12:15 p.m. in Room 2. Prof. Dr. Alexander Steinkasserer will also chair this session. The EHRS Annual Meeting is one of the leading scientific events in the field of hair biology and hair disorders, bringing together leading scientists, clinicians and industry representatives from around the world to present and discuss the latest developments in basic research and translational medicine for hair disorders. Prof. Dr. Alexander Steinkasserer commented: “With sCD83, we are pursuing a novel immunomodulatory approach to counteract hair loss and induce new hair growth. Our preclinical data show that soluble CD83 not only promotes hair growth in general, but also stimulates and prolongs the anagen growth phase of hair follicles. The EHRS conference offers an excellent platform to present this scientific approach to a About sCD83 Soluble CD83 (sCD83) is an immune-modulatory protein currently in development for the topical treatment of hair loss. The soluble CD83 protein, which was first identified in 2001 by Mallia co-founder Prof. Dr. Steinkasserer, has anti-inflammatory properties via the induction of resolution of inflammation, which promotes wound healing and induces new hair growth.[1] In addition, sCD83 has been shown to activate regulatory Topically applied, sCD83 can directly reach the hair follicles, but does not penetrate through the skin and thus has not been detected in the bloodstream. The effect is limited to the local area, which is a major advantage over systemic treatment options, some of which can cause severe side effects. About hair loss: Hormone-related hair loss in men and women (= androgenetic alopecia) is the most common form of hair loss. Worldwide, more than 70% of men and 50% of women post menopause are affected by androgenetic alopecia. Another 147 million people suffer from immune-related, circular hair loss (= alopecia areata). [2],[3] Androgenetic alopecia is the most common type of alopecia. It typically occurs gradually and is related to genetic and hormonal factors. In men, it often results in a receding hairline and baldness on the top of the head, while in women, it leads to thinning hair on the crown of the head. Alopecia areata causes patchy hair loss on the scalp, face, or other parts of the body. It occurs when the immune system “mistakenly” attacks hair follicles, resulting in an autoimmune mediated hair loss. About Mallia Therapeutics GmbH Mallia Therapeutics GmbH is a biopharmaceutical company focused on developing novel treatments for patients suffering from hair loss. The Company was founded in 2023 in Erlangen, Germany, and is led by an experienced management team and worldwide leading experts in the field of CD83, with more than 170 CD83-related publications and 20 years of experience in the field. With sCD83, a potential treatment for hair loss in preclinical development, Mallia aims to enter the multi-billion-dollar alopecia market and provide patients with a safe and effective topical treatment. Connect with us on LinkedIn or find out more here: https://mallia-therapeutics.com/. Media contact: [1] Royzman, D., Peckert-Maier, K., Stich, L., König, C., Wild, A. B., Tauchi, M., ... & Steinkasserer, A. (2022). Soluble CD83 improves and accelerates wound healing by the induction of pro-resolving macrophages. Frontiers in Immunology, 13, 1012647.: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564224/ [2] Feinstein, R. P. (2022). Androgenetic alopecia.: https://emedicine.medscape.com/article/1070167-overview [3] Mostaghimi, A., Gandhi, K., Done, N., Ray, M., Gao, W., Carley, C., ... & Sikirica, V. (2022). All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States. Journal of Managed Care & Specialty Pharmacy, 28(4), 426-434: https://www.jmcp.org/doi/pdf/10.18553/jmcp.2022.28.4.426
21.05.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
2141870 21.05.2025 CET/CEST
